Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma / 中华肿瘤杂志
Chinese Journal of Oncology
; (12): 619-620, 2002.
Article
en Zh
| WPRIM
| ID: wpr-301920
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and drug-related toxicity of combined gemcitabine, cisplatin, and prednisone for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).</p><p><b>METHODS</b>Fifteen patients with histologically confirmed relapsed or refractory aggressive NHL were included in this study. Gemcitabine was given on D1, 8 of a three to four weeks schedule at a dose of 1000 mg/m(2) intravenously over 30 minutes for no less than three cycles, and cisplatin was given on D1-3 at a dose of 25 mg/m(2). Prednisone was taken orally on D1-5 at a dose of 60 mg/m(2).</p><p><b>RESULTS</b>Of 15 patients, 11 patients (73.3%) showed responses: 5 patients (33.3%) giving complete response and 6 patients (40.0%) partial response. Four patients' symptoms disappeared, and 1 in 6 patients was alleviated of type B symptoms. Drug-related toxic effects of chemotherapy were mild gastrointestinal reactions in most patients and severe bone marrow depression in very few patients.</p><p><b>CONCLUSION</b>The present combination of gemcitabine, cisplatin, prednisone possesses moderate short-term efficacy, acceptable toxicity, and alleviation of suffering related to the disease. This protocol is worthy to be warranted as salvage for relapsed or refractory aggressive NHL.</p>
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Linfoma no Hodgkin
/
Prednisona
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Cisplatino
/
Terapia Recuperativa
/
Usos Terapéuticos
/
Desoxicitidina
/
Quimioterapia
/
Prevención Secundaria
/
Antimetabolitos Antineoplásicos
Tipo de estudio:
Guideline
Límite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
Idioma:
Zh
Revista:
Chinese Journal of Oncology
Año:
2002
Tipo del documento:
Article